Education
About Us
Working with TipRanks
Follow Us
Axsome Therapeutics Inc (AXSM)
NASDAQ:AXSM
AXSM Stock Chart & Stats
$152.65
-$0.23(-0.27%)
At close: 4:00 PM EST
$152.65
-$0.23(-0.27%)
Day’s Range― - ―
52-Week Range$75.56 - $154.49
Previous CloseN/A
Volume140.83K
Average Volume (3M)494.39K
Market Cap
$7.70B
Enterprise Value$5.97B
Total Cash (Recent Filing)$325.27M
Total Debt (Recent Filing)$218.60M
Price to Earnings (P/E)―
Beta0.84
Next Earnings
Mar 02, 2026EPS Estimate
-0.73Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.94
Shares Outstanding50,412,640
10 Day Avg. Volume428,381
30 Day Avg. Volume494,390
Financial Highlights & Ratios
PEG Ratio-1.03
Price to Book (P/B)71.10
Price to Sales (P/S)10.51
P/FCF Ratio-31.50
Enterprise Value/Market Cap0.78
Enterprise Value/Revenue10.63
Enterprise Value/Gross Profit11.58
Enterprise Value/Ebitda-28.11
Forecast
1Y Price Target
$179.17Price Target Upside17.37% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering15
EPS Forecast (FY)-3.8
Revenue Forecast (FY)$628.76M
Bulls Say, Bears Say
Bulls Say
Drug Development And ApprovalsPotential FDA acceptance of the supplemental new drug application for Auvelity in Alzheimer’s disease-related agitation is anticipated soon.
Market PerformanceAxsome's earnings release indicated that the company narrowly beat top-line expectations, signaling progress towards profitability.
Pipeline ExpansionAxsome announced it will obtain global development and commercialization rights for AZD7325 (BAER-101), a GABA positive allosteric modulator (PAM), through an acquisition of Baergic Bio.
Bears Say
Prescription Data InterpretationAnalysts recommend caution when interpreting weekly prescription data to avoid making definitive judgments about the progress of drug launches.
Prescription TrendsThe Thanksgiving holiday week resulted in a decline in Auvelity prescriptions compared to the previous week.
Regulatory UncertaintyPotential AXS-05 sNDA acceptance from the FDA for treatment of AD-A is a reason for weakness beyond macro pressures.
Axsome Therapeutics News
AXSM FAQ
What was Axsome Therapeutics Inc’s price range in the past 12 months?
Axsome Therapeutics Inc lowest stock price was $75.56 and its highest was $154.49 in the past 12 months.
What is Axsome Therapeutics Inc’s market cap?
Axsome Therapeutics Inc’s market cap is $7.70B.
When is Axsome Therapeutics Inc’s upcoming earnings report date?
Axsome Therapeutics Inc’s upcoming earnings report date is Mar 02, 2026 which is in 71 days.
How were Axsome Therapeutics Inc’s earnings last quarter?
Axsome Therapeutics Inc released its earnings results on Nov 03, 2025. The company reported -$0.94 earnings per share for the quarter, missing the consensus estimate of -$0.861 by -$0.079.
Is Axsome Therapeutics Inc overvalued?
According to Wall Street analysts Axsome Therapeutics Inc’s price is currently Undervalued.
Does Axsome Therapeutics Inc pay dividends?
Axsome Therapeutics Inc does not currently pay dividends.
What is Axsome Therapeutics Inc’s EPS estimate?
Axsome Therapeutics Inc’s EPS estimate is -0.73.
How many shares outstanding does Axsome Therapeutics Inc have?
Axsome Therapeutics Inc has 50,412,640 shares outstanding.
What happened to Axsome Therapeutics Inc’s price movement after its last earnings report?
Axsome Therapeutics Inc reported an EPS of -$0.94 in its last earnings report, missing expectations of -$0.861. Following the earnings report the stock price went up 0.563%.
Which hedge fund is a major shareholder of Axsome Therapeutics Inc?
Currently, no hedge funds are holding shares in AXSM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Axsome Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$179.17 (17.37% Upside)
$179.17 (17.37% Upside)
Blogger Sentiment
Bullish
AXSM Sentiment 100%
Sector Average 68%
Sector Average 68%
Hedge Fund Trend
Decreased
By 127.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 6.3%
Last 30 Days ▼ 6.3%
Technicals
SMA
Positive
20 days / 200 days
Momentum
70.10%
12-Months-Change
Fundamentals
Return on Equity
-275.50%
Trailing 12-Months
Asset Growth
19.20%
Trailing 12-Months
Company Description
Axsome Therapeutics Inc
Axsome Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for the management of central nervous system (CNS) disorders. The company specializes in the research and development of novel treatments for conditions such as depression, migraine, and pain, leveraging its proprietary drug candidates and innovative delivery methods to address unmet medical needs. Axsome's core products include AXS-05, an investigational treatment for major depressive disorder, and AXS-07, a novel therapy for acute migraine treatment.
AXSM Company Deck
AXSM Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Axsome Therapeutics reported strong revenue growth and product performance, supported by strategic commercial execution and a robust R&D pipeline. However, increased expenses and ongoing net losses present financial challenges.View all AXSM earnings summariesAXSM Stock 12 Month Forecast
Average Price Target
$179.17
▲(17.37% Upside)
Technical Analysis
Cytokinetics
―
Rhythm Pharmaceuticals
―
Legend Biotech
―
Avidity Biosciences
―
Nuvalent
―
Ownership Overview
15.70% Insiders
22.36% Mutual Funds
25.11% Other Institutional Investors
23.85% Public Companies and Individual Investors